Recent Posts
- Illinois Attorney General Files Lawsuit Against HIV/AIDS Nonprofit
- California Gov. Arnold Schwarzenegger Signs Budget That Cuts $52M From HIV/AIDS Programs
- Efforts Underway In Namibia To Treat Pediatric HIV
- HIV/AIDS Education Project Targeting Pennsylvania Black Women Examined
- Also In Global Health News: Uganda Male Circumcision; Malaria Vaccine; Potential Global Fund Grant In Cambodia; PMTCT Of HIV In Botswana
Random Posts
- Chicago-Based Consortium Awarded Major Grant From NIH To Create Center For AIDS Research
- Proteomics Technology To Focus On Neurological Complications Of HIV
- Certain Cancers More Common Among HIV Patients Than Non-HIV Patients
- Also In Global Health News: News Outlets Explore AIDS Vaccine Research; Chloroquine Resistance Unraveled; Authorities Contest Maternal Mortality Rep.
- Editorial Discusses Needle Exchange Restrictions Included In House Bill
- Why Circumcision Reduces HIV Risk
- Also In Global Health News: Funding Shortfall In Philippines; WHO-Approved ARV
- Social, Sexual Barriers Faced By Black Gay Men Could Influence HIV Risk, Prevalence, Study Says
- HIV/AIDS Vaccine Coalition Urges Continued Funding For Research Amid Economic Crisis
- Also In Global Health News: Polio Vaccines In Nigeria; Health Care In Indonesia; Circumcision To Prevent HIV/AIDS In Botswana
Prescription AIDS Drugs
Contact Us
Viriom Selects ChemDiv To Develop HIV Program
April 14th, 2010
ChemDiv, Inc. (ChemDiv) of San Diego has proudly announced that its wholly owned subsidiary Chemical Diversity Research Institute (CDRI ) of Moscow, Russia, has been chosen by Viriom Ltd. ( Viriom) of Moscow, Russia as a service partner in developing innovative HIV compounds. The program includes pre-clinical and clinical studies, which are expected to begin in 2010.
Viriom has recently signed the license agreement with Roche. Under the terms of this agreement Roche granted Viriom development and commercialization rights for potential novel HIV/AIDS medicine in Russia, Ukraine, Belarus and Kazakhstan. Subject to performance of the program Viriom will also receive license fees, development milestones and royalties on worldwide sales.
Vadim Bichko, Vice President Virology at ChemDiv, Inc., said: “We are excited about this new collaboration with Viriom and Roche. These novel HIV inhibitors have shown excellent antiviral properties in vitro, good bioavailability, PK and safety profiles, as well as a high genetic barrier to resistance. Based on pre-clinical studies to date, these molecules have the potential to become best in class HIV drugs.”
About VIRIOM
VIRIOM Ltd. is an innovative company that was established in 2009 to develop targeted medicines for HIV/AIDS. Basis is the Center of High Technologies ChemRar to which VIRIOM is affiliated. VIRIOM is planning to conduct research and clinical trials in Russia using the experience and knowledge of Russian scientists. Chemical Diversity Research Institute, Prudentas Ltd. and Drug Technologies Ltd.of ChemRar Hi Tech Center (ChemRar) as well as Moscow City Center for prevention and treatment of HIV/AIDS were selected as partners in this program.
About ChemDiv, Inc.
ChemDiv collaborates with pharmaceutical and biotech partners by enabling them to accelerate their R&D programs to higher value clinical inflection points. ChemDiv provides integrated drug discovery and early clinical development, extracting value from potential therapeutic candidates via rapid, streamlined outcomes and effective use of capital.
ChemDiv is the only vertically and horizontally integrated discovery and development CRO headquartered in San Diego, CA, with: unique access to the Eastern European emerging pharma market; rational drug design and medicinal chemistry in a broad range of therapeutic areas of target classes; world’s largest small molecule inventory; working with 20 top pharma and 100 top biotechs in all major markets.
With its successful 20 year business record in life sciences and over 500 research associates equivalent employed globally, ChemDiv has successfully prosecuted fully integrated programs from target to Proof of Concept (POC) and market registration.
About Chemical Diversity Research Institute.
CDRI is a contract research organization focused on pre-clinical and clinical R&D. CDRI sees its mission in enabling discovery and development of innovative therapies for unmet needs utilizing the highest expertise and innovation potential of Russian scientists with integrated external R&D solutions of Discovery outSource™ platforms. Discovery outSource™ platform solutions cover the complete range of disciplines from identification of a biological target (protein expression, assay development etc.); to clinical drug candidates (ADME/DMPK, toxicity and safety studies, in vivo animal models, drug formulation etc.); to drug development candidate (Phase I to Phase IV).
Source
ChemRar Hi Tech Center
Related posts:
- Leading Vaccine Discovery Expert Joins The International AIDS Vaccine Initiative (IAVI) Dr. C. Richter (Rick) King, former Senior Vice President of...
- Researchers Develop Vaccine Candidate That Is Successful In Blocking Simian Version Of HIV Researchers have successfully blocked SIV, the simian version of HIV,...
- Focusing On The HIV Virus: £1.7M Award To Develop Nanotechnology For Use In Health Care Scientists at the University of Liverpool have been awarded £1.7...
- Einstein To Develop Anti-HIV Drug Delivery System The National Institutes of Health has awarded Albert Einstein College...
- Gilead Sciences, Tibotec To Develop Second Once-Daily HIV Treatment Patient / Public: 5 (1 votes) Health Professional: Article...
Related posts brought to you by Yet Another Related Posts Plugin.
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.